Today, the US Food and Drug Administration (FDA) approved Opill (norgestrel) tablet for non-prescription use to prevent pregnancy - the first daily oral contraceptive approved for use in the USA without a prescription.
The FDA granted the approval to Laboratoire HRA Pharma, recently acquired by Perrigo Company (NYSE: PRGO), which said that Opill will be available in store and online at leading retailers across the USA early in the first quarter of 2024.
Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze